The AstraZeneca PLC ADR AZN slumped 0.66% to $78.38 Friday, on what proved to be an all-around mixed trading session for the ...

(Alliance News) - AstraZeneca PLC on Friday announced that its influenza vaccine FluMist has been approved for self-administration in the US. The Cambridge, England-based biopharmaceutical company ...

The Food and Drug Administration announced Friday it had broadened the approval of the FluMist nasal spray to become the ...

The FDA is clearing the way for an at-home flu vaccines. A self-administered version of pharmaceutical giant AstraZeneca’s ...

FluMist is the first vaccine to prevent influenza that does not need to be administered by a healthcare provider, the ...

The Food and Drug Administration (FDA) announced Friday it has approved the first flu vaccine that can be self-administered, ...

The US Food and Drug Administration on Friday approved the first flu vaccine that does not have to be administered by a ...

The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's nasal spray flu vaccine for ...

The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's influenza nasal spray vaccine for ...

The latest trading day saw Astrazeneca (AZN) settling at $78.38, representing a -0.66% change from its previous close.

Key Insights ...

AstraZeneca has just scored big on the quest to make routine vaccinations less of a hassle. | The FDA signed off on ...